August 24, 2023
August 24, 2023 - The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first
biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
August 18, 2023
Aug. 18, 2023 - Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Eylea
August 18, 2023
August 18, 2023 - Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved VeopozTM (pozelimab-bbfg)
August 16, 2023
August 16, 2023 – Ipsen has announced approval by the U.S. Food and Drug Administration (FDA) of SohonosTM (palovarotene) capsules as a retinoid indicated
August 14, 2023
August 14, 2023 – Revance Therapeutics, Inc. has announced that the United States (U.S.) Food and Drug
Administration has approved the first therapeutic
August 14, 2023
August 14, 2023 - Delcath Systems, Inc., has announced that the US Food and Drug Administration (FDA)
approved Hepzato Kit (melphalan/Hepatic Delivery System)
August 14, 2023
August 14, 2023 - Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has granted
accelerated approval to Elrexfio™ (elranatamab-bcmm) for the treatment
August 14, 2023
On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Pfizer’s
Elrexfio (elranatamab-bcmm), a bispecific B-cell maturation